Metformin: An effective attenuator of risperidone-induced insulin resistance hyperglycemia and dyslipidemia in rats

Indian Journal of Experimental Biology

Volumn 49, Issue 5, 2011, Pages 332-338

  Adeneye, Adejuwon A ^a,b   Agbaje, Esther O ^c   Olagunju, Joseph A ^b  

^a University of Kentucky   (United States)

^b LAGOS STATE UNIVERSITY   (Nigeria)

^c UNIVERSITY OF LAGOS   (Nigeria)

Author keywords

Glibenclamide; Insulin resistance; Metformin; Rats; Risperidone

Indexed keywords

ANTIDIABETIC AGENT; GLIBENCLAMIDE; LIPID; METFORMIN; NEUROLEPTIC AGENT; RISPERIDONE;

ANIMAL; ARTICLE; BLOOD; CHEMICALLY INDUCED DISORDER; DISEASE MODEL; DRUG EFFECT; DYSLIPIDEMIA; GLUCOSE BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; INSULIN RESISTANCE; MALE; METABOLISM; RAT; WEIGHT GAIN; WISTAR RAT;

ANIMALS; ANTIPSYCHOTIC AGENTS; BLOOD GLUCOSE; DISEASE MODELS, ANIMAL; DYSLIPIDEMIAS; GLYBURIDE; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; LIPIDS; MALE; METFORMIN; RATS; RATS, WISTAR; RISPERIDONE; WEIGHT GAIN;

RATTUS; RATTUS NORVEGICUS;

EID: 79957456091     PISSN: 00195189     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. Baker R A, Pikalov A, Tran Q-V, Kremenets T, Arani R B & Doraiswanay P M, Atypical antipsychotic drugs and diabetes mellitus in the US Food and Drug Administration Adverse Events Database: A Systematic Bayesian Signal Detection Analysis, Psychopharmacol Bull, 42 (1) (2009) 1.
2. Saha S, Chant D, Welham J & McGrath J, A systematic review of the prevalence of schizophrenia, PLoS Med, 2(5) (2005) e141.
3. Axelsson R & Lagerkvist-Briggs M, Factors predicting suicide in psychotic patients, Eur Arch Psychiatry Clin Neurosci, 241(5) (1992) 259.
4. Henderson D C, Schizophrenia and comorbid metabolic disorders, J Clin Psychiatry, 66(Suppl 6) (2005) 11.
5. Barnett A, Mackin P, Chaudhy I, Farooqi A, Gadsby R, Heald A, Hill J, Millar H, Peveler R, Rees A, Singh V, Taylor D, Vora J & Jones P, Minimising metabolic and cardiovascular risk in schizophrenia: diabetes, obesity and dyslipidemia, J Psychopharmacol, 21(2007) 357.
6. Glassman A H, Schizophrenia, antipsychotic drugs and cardiovascular disease, J Clin Psychiatry, 66 (2005) 5.
7. Kaptsan A, Dwoltazky T & Lerner V, Ziprasidone-associated depressive state in Schizophrenic patients, Clin Neuropharmacol, 30 (2007) 357.
8. Hennen J & Baldessarini R J, Suicidal risk during treatment with clozapine: a meta-analysis, Schizoph Res, 73 (2005) 139.
9. Tarsy D, Baldessarini R J & Tarazi F I, Extra-pyramidal dysfunction associated with modern antipsychotic drugs, CNS Drugs, 16 (2002) 23.
10. Lean M E J & Pajonk F G, Patients on atypical antipsychotic drugs: Another high-risk group for type 2 diabetes, Diabetes Care, 26 (2003) 1597.
11. Koller E A & Doraiswamy P M, Olanzapine-associated diabetes mellitus. Pharmacotherapy, 22 (2002) 841.
12. Bonanno D G, Davydov L & Botts S R, Olanzapine-induced diabetes mellitus. Ann Pharmacother, 35 (2001) 563.
13. Dixon L, Weiden P, Delahanty J, Goldberg R, Postrado L, Lucksted A & Lehman A, Prevalence and correlates of diabetes in national schizophrenia samples, Schizophr Bull, 26 (2000) 903.
14. Harris M I, Flegal K M, Cowie C C, Eberhardt M S, Goldstein D E, Little R R, Wiedmeyer H M & Byrd-Holt D D, Prevalence of diabetes, impaired fasting glucose tolerance in US adults: the Third National Health and Nutrition Examination Survey, 1988-1994, Diabetes Care, 21 (1998) 518.
15. Liebzeit K A, Markowitz J S & Caley C F, New onset diabetes and atypical antipsychotics. Eur J Neuropsychopharm, 11 (2001) 25.
16. Mir S & Taylor D, Atypical antipsychotics and hyperglycemia, Int J Clin Psychopharm, 16 (2001) 63.
17. Davis S N & Granner D K, Insulin, oral agents, and the pharmacology of the endocrine pancreas, in Goodman and Gilman's the pharmacological basis of therapeutics, edited by Hardman J G, Limbird L E & Gilman A G (McGraw-Hill Companies Incorporation, New York, U.S.A.) 2001, 1679.
18. Koller E A, Cross J T, Doraiswamy P M & Schneider B S, Risperidone-associated diabetes mellitus: a pharmacovigilance study, Pharmacotherapy, 23 (2003) 735.
19. United States National Institutes for Health, Guide for the care and use of laboratory animals, no. 25 (1985).
20. World Health Organization, Second report of the WHO expert committee on diabetes mellitus, Technical Report Series 646 (1980) 66.
21. Adeneye A A & Adeyemi O O, Further evaluation of antihyperglycemic activity of Hunteria umbellata (K. Schum.) Hallier f. seed extract in experimental diabetes, J Ethnopharmacol, 126 (2009) 238.
22. Tripathy D, Almgren P, Tuomi T & Groop L, Contribution of insulin-stimulated glucose uptake and basal hepatic insulin sensitivity to surrogate measures of insulin sensitivity, Diabetes Care, 27(9) (2004) 2204.
23. Anderson L, Dinesen B, Jorgesen P N, Poulsen F & Roder M F, Enzyme immunoassay for intact human insulin in serum or plasma, Clin Chem, 39 (1993) 578.
24. Ambler J, Janik B & Walker G, Measurement of glycosylated hemoglobin on cellulose acetate membranes by mobile affinity electrophoresis, Clin Chem, 29 (1983) 340.
25. Harati M, Ani M & Messripour M, Effect of vanadyl sulphate on fructose induced insulin resistance rat, Iran Biomed Res, 7 (2003) 179.
26. Shalam M D, Harish M S & Farhana S A, Prevention of dexamethasone-and fructose-induced insulin resistance in rats by SH-01D, a herbal preparation, Indian J Physiol Pharmacol, 38 (2006) 419.
27. Liberty I F, Todder D, Umansky R & Herman-Boehm I, Atypical antipsychotics and diabetes mellitus: an association, IMAJ, 6 (2004) 276.
28. Casey D E, Haupt D W, Newcomer J W, Henderson D C, Sernyak M J, Davidson M, Lindenmayer J P, Manoukian S V, Banerji M A, Lebovitz H E & Hennekens C H, Antipsychotic-induced weight gain and metabolic abnormalities: Implications for increased mortality in patients with schizophrenia, J Clin Psychiatry, 65(Suppl 7) (2004) 4.
29. Markowitz J S, Brown C S & Moore T R, A typical antipsychotics. Part I: Pharmacology, pharmacokinetics and efficacy, Ann Pharmacother, 33 (1999) 73.
30. Lipscombe L L, Levesque L, Gruneir A, Fischer H D, Juurlink DN, Gill SS, Herrmann N, Hux JE, Anderson G M & Rochon PA, Antipsychotic drugs and hyperglycemia in older patients with diabetes, Arch Intern Med, 169(14) (2009) 1282.
31. Lipscombe L L & Hux J E, Trends in diabetes prevalence, incidence, and mortality in Ontario, Canada. 1995-2005: a population-based study, Lancet, 369 (2007) 750
32. Gianfrancesco F, Pesa J, Wang H & Nasrallah H A, Assessment of antipsychotic-related risk of diabetes mellitus in a Medicaid psychosis population: sensitivity to study design, Am J Health Syst Pharm, 63(5) (2006) 431.
33. Wirshing D A, Boyd J A, Meng L R, Ballon J S, Marder S R & Wirshing W C, The effects of novel antipsychotics on glucose and lipid levels, J Clin Psychiatry, 63 (2002) 856.
34. Rigalleau V, Gatta B, Bonnaud S, Bourgeois M L, Vergnot V & Gin H, Diabetes as a result of atypical antipsychotic drugs: A report of three cases, Diabet Med, 17 (2000) 484.
35. Yazici K M, Erbas T & Yazici A H, The effect of clozapine on glucose metabolism, Exp Clin Endocrinol Diabetes, 106 (1998) 475.
36. Hagg S, Soderberg S, Ahren B T., Olsson T & Mjorndal T, Leptin concentrations are increased in subjects treated with clozapine or conventional antipsychotics, J Clin Psychiatry, 62 (2001) 843.
37. Ardizzone T D, Bradley R J, Freeman A M III & Dwyer D S, Inhibition of glucose transport in PC12 cells by the atypical antipsychotic drugs risperidone and clozapine and structural analogs of clozapine, Brain Res, 27 (2001) 82.
38. Jacobs D B, Hayes G R & Lockwood D H, In vitro effects of sulfonylureas on glucose transporters in adipocytes from streptozotocin-induced diabetic rats, Diabetes, 38 (1989) 205.
39. Stumvoll M, Nurjan N, Perriello G, Dailey G & Gerich J E, Metabolic effects of metformin in non-insulin-dependent diabetes mellitus, N Eng J Med, 333 (1995) 550.
40. Allison D B, Mentore J L, Heo M, Chandler L P, Cappelleri J C, Infante M C & Weiden P J, Antipsychotic-induced weight gain: a comprehensive research synthesis, Am J Psychiatry, 156 (1999) 1686.
41. DeFronzo R A, Goodman A M & the Multicenter Metformin Study Group, Efficacy of metformin in patients with noninsulin dependent diabetes mellitus, N Eng J Med, 333 (1995) 541.
42. Bays H E, Current and Investigational anti-obesity agents and obesity therapeutic treatment targets, Obesity Res, 12 (2004) 1197.
43. Matthaei S, Reibold J P, Hamann A, Benecke H, Häring H U, Greten H & Klein H H, In vivo metformin treatment ameliorates insulin resistance: evidence for potentiation of insulin-induced translocation and increased functional activity of glucose transporters in obese (fa/fa) Zucker rat adipocytes, Endocrinology, 133 (1993) 304.
44. Abbasi F, Carantoni M, Chen Y D & Reaven G M, Further evidence for a central role of adipose tissue in the antihyperglycemic effect of metformin, Diabetes Care, 21 (1998) 1301.